Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 27, 2019	Sep. 28, 2018	Sep. 27, 2019	Sep. 28, 2018
Net sales		$ 743.7	$ 799.9	$ 2,357.6	$ 2,380.7
Operating Income (Loss)	[1]	8.3	69.5	(6.2)	148.3
Intangible asset amortization		(210.4)	(184.2)	(649.8)	(546.5)
Restructuring and related charges, net		(7.2)	(19.6)	(11.2)	(106.6)
Non-restructuring impairment charge		0.0	(2.0)	(113.5)	(2.0)
Specialty Brands
Restructuring and related charges, net		0.0	(4.9)	(0.4)	(52.4)
Operating Segments
Operating Income (Loss)		289.1	304.5	944.3	889.1
Operating Segments | Specialty Brands
Net sales		580.4	640.0	1,812.4	1,844.3
Operating Income (Loss)		267.3	288.0	864.2	794.4
Operating Segments | Specialty Generics
Net sales		163.3	159.9	545.2	536.4
Operating Income (Loss)		21.8	16.5	80.1	94.7
Corporate, Non-Segment
Corporate and unallocated expenses	[2]	(23.4)	(29.2)	(105.6)	(85.7)
Intangible asset amortization		(210.4)	(184.2)	(649.8)	(546.5)
Restructuring and related charges, net		(7.2)	(19.6)	(11.2)	(106.6)
Non-restructuring impairment charge		0.0	(2.0)	(113.5)	(2.0)
Separation Costs	[3]	(19.8)	0.0	(50.4)	0.0
R&D upfront payment	[4]	$ (20.0)	0.0	$ (20.0)	0.0
Sucampo [Member]
Operating Income (Loss)			32.2		99.9
Intangible asset amortization			(18.0)		(45.0)
Cost of Sales [Member] | Sucampo [Member]
Amortization Of Inventory Step-Up To Cost Of Sales			$ 31.0		$ 77.5

[1] The amount of operating loss included in the Company's unaudited condensed consolidated statement of income for the three and nine months ended September 28, 2018 related to the Sucampo Acquisition was $32.2 million and $99.9 million, respectively. Included within these results were $18.0 million and $45.0 million of amortization associated with intangibles recognized from this acquisition and $31.0 million and $77.5 million of expense associated with fair value adjustments of acquired inventory for the three and nine months ended September 28, 2018, respectively.

[2] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

[3] Represents costs incurred related to the separation of the Company's Specialty Generics segment, inclusive of costs related to the suspended spin-off of that business and rebranding costs associated with the Specialty Brands ongoing transformation, all of which are included in SG&A.

[4] Represents R&D expense incurred related to an upfront payment made to Silence in connection with the license and collaboration agreement entered into in July 2019. Refer to Note 15 for further details.